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ABSTRACT
During the ESC congress in September 2019 in Paris, the new ESC guidelines were presented
and are now available on the ESC website. The new guidelines describe management recom-
mendations on following cardiovascular diseases: chronic coronary syndromes, acute pulmonary
embolism, supraventricular tachycardia and dislipidaemias. The present document gives a sum-
mary of these guidelines and highlights the most important recommendations and changes in
the management of these diseases. It will help to increase awareness about the new guidelines
and may stimulate to consult the full document for specific items. Ultimately, the authors hope
that this document will enhance implementation of new ESC guidelines in daily clinical practice.
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ESC guidelines for the diagnosis and
management of chronic coronary
syndromes (CCS)
The Guidelines have been revised to focus on CCS
instead of stable CAD in order to emphasise the fact
that the clinical presentations of CAD can be cate-
gorised as either acute coronary syndromes (ACS) or
CCS [1]. Six clinical scenarios most frequently
encountered in patients have been identified: from
naive and asymptomatic patients to symptomatic
patients (angor/dyspnea) presenting after an ACS.
The pre-test probability (PTP) of CAD based on age,
gender and nature of symptoms have undergone
major revisions and the concept ‘Clinical likelihood
of CAD’ has been introduced that utilises also vari-
ous risk factors of CAD as PTP modifiers (Figures 1
and 2). New recommendations can be divided in
three categories:
1. Basic testing, diagnostics, and risk assessment
 Non-invasive functional imaging for myocardial
ischaemia or coronary computed tomography
(CTA) is recommended (Class I) as the initial
test for diagnosing CAD in symptomatic
patients in whom obstructive CAD cannot be
excluded by clinical assessment alone.
 Exercise ECG is now only recommended for
the assessment of exercise tolerance, symp-
toms, arrhythmias, blood presure (BP)
response, and event risk in selected patients. It
has been downgraded in II B category as an
alternative test to rule-in or rule-out CAD when
other non-invasive or invasive imaging meth-
ods are not available and in patients on treat-
ment to evaluate control of symptoms
and ischaemia.
 It is also recommended that selection of the
initial non-invasive diagnostic test be based on
the clinical likelihood of CAD and other patient
characteristics that influence test performance,
local expertise, and the availability of tests.
 Functional imaging for myocardial ischaemia is
recommended if coronary CTA has shown CAD
of uncertain functional significance or is
not diagnostic.
 Invasive angiography is recommended as an
alternative test to diagnose CAD in patients
with a high clinical likelihood and severe
symptoms refractory to medical therapy, or
typical angina at a low level of exercise and
clinical evaluation that indicates high event
risk. Invasive functional assessment must be
available and used to evaluate stenoses before
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revascularization, unless very high grade
(>90% diameter stenosis).
 Invasive coronary angiography with the avail-
ability of invasive functional evaluation should
be considered (Class IIA) for confirmation of
the diagnosis of CAD in patients with an
uncertain diagnosis on non-invasive testing.
 Coronary CTA should be considered as an alter-
native to invasive angiography if another non-
invasive test is equivocal or non-diagnostic.
 Importantly, CTA is not recommended (Class III)
when extensive coronary calcification, irregular
heart rate, significant obesity, inability to cooper-
ate with breath-hold commands, or any other
conditions make good image quality unlikely.
2. Antithrombotic therapy in patients with CCS
 Addition of a second antithrombotic drug to
aspirin for long-term secondary prevention should
be considered (Class IIA) in patients with a high
risk of ischaemic events and without high bleed-
ing risk for patients with CCS and in sinus rhythm
and may be considered (Class IIB) in patients with
at least a moderately increased risk of ischaemic
events and without high bleeding risk.
 In patients with CCS and atrial fibrillation (AF)
a direct oral anticoagulant (DOAC) is recom-
mended (Class I) in preference to a vitamin K
antagonists (VKA) in eligible patients.
 In patients with CCS and post-PCI, who are eli-
gible for a DOAC, it is recommended that a
DOAC (apixaban 5mg b.i.d., dabigatran 150mg
b.i.d., edoxaban 60mg o.d., or rivaroxaban
20mg o.d.) is used in preference to a VKA in
combination with antiplatelet therapy. (Class I)
 In the same population, several Class IIA spe-
cific recommendations are provided for specific
antithrombotic treatment: when rivaroxaban is
used and concerns about high bleeding risk
prevail over concerns about stent thrombosis
or ischaemic stroke, rivaroxaban 15mg o.d.
should be considered in preference to rivaroxa-
ban 20mg o.d. for the duration of concomitant
single or dual antiplatelet therapy. When dabi-
gatran is used and concerns about high bleed-
ing risk prevail over concerns about stent
thrombosis or ischaemic stroke, dabigatran
110mg b.i.d. should be considered in prefer-
ence to dabigatran 150mg b.i.d. for the dur-
ation of concomitant single or dual
antiplatelet therapy.
 After uncomplicated PCI, early cessation
(1 week) of aspirin, and continuation of dual
therapy with OAC and clopidogrel, should be
Figure 1. Pre-test probabilities of obstructive CAD in 15815 symptomatic patients according to age, sex, and the nature of symp-
toms in a pooled analysis of contemporary data. CAD: coronary artery disease; PTP: pre-test probability. aIn addition to the classic
Diamond and Forrester classes,59 patients with dyspnoea only or dyspnoea as the primary symptom are included. The regions
shaded dark green denote the groups in which non-invasive testing is most beneficial (PTP > 15%). The regions shaded light
green denote the groups with PTPs of CAD between 5–15%, in which testing for diagnosis may be considered after assessing the
overall clinical likelihood based on the modifiers of PTPs presented in Figure 4.
Figure 2. Determinants of the clinical likelihood of obstruct-
ive CAD.
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considered if the risk of stent thrombosis is
low or if concerns about bleeding risk prevail
over concerns about risk of stent thrombosis,
irrespective of the type of stent used.
 Triple therapy with aspirin, clopidogrel, and an
OAC for 1 month should be considered
when the risk of stent thrombosis outweighs
the bleeding risk, with the total duration
(6 months) decided upon according to the
assessment of these risks and clearly specified
at hospital discharge.
3. Other pharmacological therapy
 Concomitant use of a proton pump inhibitor is
recommended (Class I) in patients receiving
aspirin monotherapy, DAPT, or OAC monother-
apy who are at high risk of gastrointes-
tinal bleeding.
 Lipid-lowering drugs: for patients at very
high risk who do not achieve their goals on
a maximum tolerated dose of statin and
ezetimibe, combination with a PCSK9 inhibi-
tor is Class I.
 The sodium-glucose co-transporter 2 inhibitors
empagliflozin, canagliflozin, or dapagliflozin are
recommended (Class I) in patients with dia-
betes mellitus and cardiovascular disease (CVD)
as well as glucagon-like peptide-1 receptor
agonist (liraglutide or semaglutide).
 ACE inhibitors should be considered (Class IIA)
in CCS patients at very high risk of cardiovas-
cular adverse events.
ESC guidelines for the management of acute
pulmonary embolism (PE)
Pulmonary embolism (PE) remains a major life-threat-
ening condition. In the new ESC guidelines 2019 on
the management of PE, the focus has been on the
optimal diagnosis, evaluation and treatment with the
goal to decrease variation in practice in treating PE
and improve patient outcomes [2].
The ESC Task Force also selected a set of key rules
to guide physicians, the most important and those
that were new or revisited are listed below.
1. Diagnosis
 In patients presenting with haemodynamic
instability, perform bedside transthoracic
Figure 3. Diagnostic algorithm for patients with suspected pulmonary embolism. CTPA: computed tomography pulmonary angi-
ography; PE: pulmonary embolism.
ACTA CARDIOLOGICA 3
echocardiography as a fast, immediate step to
differentiate suspected high-risk PE from other
acute life-threatening situations.
 Use recommended, validated diagnostic
algorithms for PE, including standardised
assessment of (pre-test) clinical probability and
D-dimer testing (Figure 3).
 A D-dimer test, using an age-adjusted cut-off
or adapted to clinical probability, should be
considered as an alternative to the fixed cut-
off level (IIa).
 The finding of a proximal DVT in patients sus-
pected of having PE on compression venous
ultrasonography (CUS) is considered sufficient
to confirm PE further risk assessment risk
assessment should be considered to guide
management (IIa).
2. Risk assessment
 Stratify patients with suspected or confirmed
PE, based on the presence of haemodynamic
instability, to identify those at high risk of early
mortality (I).
 Confirmation of PE in a patient, without
haemodynamic instability, must be followed by
further risk assessment involving clinical find-
ings, evaluation of the size and/or function of
the right ventricle, and laboratory biomarkers
as appropriate (Figure 3).
 Assessment of the RV by imaging or laboratory
biomarkers should be considered, even in the
presence of a low pulmonary embolism sever-
ity index. PESI or a sPESI of 0 (IIa).
3. Treatment in the acute phase (Figure 4)
 If you suspect acute PE, institute anticoagula-
tion therapy as soon as possible, while the
diagnostic workup is ongoing, unless the
patient is bleeding or has absolute contraindi-
cations to this therapy
 Administer systemic thrombolytic therapy to
patients with high-risk PE (cardiac arrest,
obstructive shock, persistent hypotension) (I).
 Rescue thrombolytic therapy is recommended for
patients who deteriorate haemodynamically (I).
 Surgical embolectomy or catheter-directed
treatment should be considered as alternatives
to rescue thrombolytic therapy for patients
who deteriorate haemodynamically (IIa).
 If anticoagulation is initiated parenterally in a
patient without haemodynamic instability, pre-
fer LMWH or fondaparinux over UFH (I).
 When oral anticoagulation is initiated in a
patient with PE who is eligible for a DOAC
(apixaban, dabigatran, edoxaban, or rivaroxa-
ban), a DOAC is the recommended form of
anticoagulant treatment (I).
 Set-up of multidisciplinary teams for manage-
ment of high-risk and selected cases of inter-
mediate-risk PE should be considered,
depending on the resources and expertise
available in each hospital (IIa).
4. Chronic treatment and prevention of recurrence
 Administer therapeutic anticoagulation for
3 months to all patients with PE (I).
 Routine clinical evaluation is recommended
3–6 months after acute PE (I).
 Discontinue therapeutic oral anticoagulation
after 3 months in patients with first PE second-
ary to a major transient/reversible risk factor (I).
 Indefinite treatment with a VKA is recom-
mended for patients with antiphospholipid
antibody syndrome (I).
 Extended anticoagulation should be consid-
ered for patients with no identifiable risk factor
for the index PE event (IIa).
 Extended anticoagulation should be considered
for patients with a persistent risk factor other
than antiphospholipid antibody syndrome (IIa).
 Extended anticoagulation should be consid-
ered for patients with a minor transient/revers-
ible risk factor for the index PE event (IIa).
 A reduced dose of apixaban or rivaroxaban should
be considered after the first 6 months (IIa).
 It is recommended that symptomatic patients
with mismatched perfusion defects on a V/Q
scan >3 months after acute PE are referred to
a pulmonary hypertension/CTEPH expert
centre, taking into account the results of echo-
cardiography, natriuretic peptide, and/or car-
diopulmonary exercise testing (I).
5. PE in cancer
 In patients with PE and cancer edoxaban or
rivaroxaban should be considered as an alter-
native to LMWH, with the exception of patients
with gastrointestinal cancer (IIa). In addition,
extended anticoagulation (beyond the first 6
months) should be considered for an indefinite
period or until cancer is cured.
ESC guidelines for the management of
supraventricular tachycardia (SVT)
This is the first update of the guidelines on manage-
ment of supraventricular tachycardia since 2003 [3].
The most important messages are:
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1. The treatments of choice for acute therapy of
supraventricular tachycardia are vagal manoeuvers
and adenosine IV (IB) and may also provide
important diagnostic information; verapamil, dil-
tiazem and beta-blockers receive recommendation
IIa. The registration of a twelve lead ECG during
tachycardia and also during acute treatment are
recommended (IC).
2. Sinus tachycardia
 Inappropriate sinus tachycardia:
 first evaluation and treatment of reversible
underlying causes (IC).
 beta blockers and/or Ivabradine should be
considered (IIa).
 catheter ablation and calcium antagonists
are not mentioned.
 Sinus atrial re-entry tachycardia:
When not responsive to drugs, catheter abla-
tion should be considered (IIa).
3. In all re-entrant supraventricular tachycardia and
most focal supraventricular tachycardia catheter
ablation is offered as initial treatment to patients
after having explained in detail potential risks
and benefits.
Figure 4. Management algorithm for patients with acute pulmonary embolism. CTPA: computed tomography pulmonary angiog-
raphy; PE: pulmonary embolism, PESI: Pulmonary Embolism Severity Index; RV: right ventricular; sPESI: Simplified Pulmonary
Embolism Severity Index; TTE: trans thoracic echocardiography.
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4. Ablation of post AF ablation atrial tachycardia
should be deferred 3 months after ablation
when possible.
5. Catheter ablation in symptomatic and recurrent
AVNRT (recommendation IB) can now be realised
with almost no risk of AV block.
6. In macro re-entrant atrial tachycardia (flutter)
without atrial fibrillation anticoagulation should
be considered (IIa). But the threshold for initiation
has not been established.
7. Asymptomatic pre-excitation (WPW) see risk strati-
fication diagram.
 One in five patients develops arrhythmias dur-
ing follow-up. Risk of cardiac arrest is 2.4 per
1000 person-years.
 Non-invasive tests may be considered (IIb) risk
stratification and its predictive ability
remains modest.
 Invasive testing (EPS) is recommended in
patients with asymptomatic pre-excitation and
high-risk occupation or competitive athletes
(IB) and should be considered in all others (IIa).
 Catheter ablation is recommended in asymp-
tomatic patients with shortest RR interval
250ms during AF, refractory periods of acces-
sory pathway <250ms, multiple accessory
pathways and if inducible AVRT(IC) (Figure 5).
 Catheter ablation should be considered in
asymptomatic low-risk patients (IIb).
8. Supraventricular tachycardia in pregnant woman:
 During the first trimester it is recommended
that all antiarrhythmic drugs are avoided (IC).
 In SVT without WPW beta- I selective blocker
(except atenolol) or Verapamil should be con-
sidered (IIa).
 In WPW without structural heart disease or
ischaemic heart disease flecaïnide or propafe-
none should be considered (IIa).
 Fluoroless ablation should be considered in
cases of drug-refractory or poorly tolerated
Figure 5. Risk stratification and therapy of patients with asymptomatic pre-excitation.
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supraventricular tachycardia, in experienced
centres (IIa).
9. Tachycardia-induced cardiomyopathy (TCM)
 TCM is one of the very few reversible causes of
heart failure and should be considered in all
new cases of LV dysfunction (IB).
 Ablation is the treatment of choice in tachy
cardiomyopathy due to supraventricular tachy-
cardia (IB).
 AV nodal ablation with subsequent biventricu-
lar or HIS bundle pacing (ablateþpace) should
be considered if the supraventricular tachycar-
dia cannot be cured (IC).
ESC guidelines for the management of
dyslipidaemias
Several recent landmark studies made the European
Society of Cardiology (ESC) and the European
Atherosclerosis Society (EAS) dyslipidemia revise their
management guidelines [4]. This is a short summary
of the main modifications with this new document, in
comparison to the previous Joint European Society of
Cardiology (ESC)/European Atherosclerosis Society
(EAS) Dyslipidaemia guidelines published 3 years ago.
 Cardiovascular risk levels
The different established risk levels (Figure 6) are
based on the best available evidence. It should be
stressed that very high-risk levels not only apply to
patients with established atherosclerotic cardiovascular
disease (ASCVD) but also to some high-risk patients in
the setting of primary prevention.
In subjects at low to moderate risk, arterial plaque
burden by means of ultrasonography (carotid and/or
femoral) or coronary artery calcium score are recom-
mended risk modifiers.
 Lower low-density lipoprotein (LDL) goals to be
achieved in high and very high-risk patients
It is now recommended that very high-risk patients, in
secondary but also in primary prevention, achieve
LDL-C levels of <55mg/dL (<1.4mmol/L) and at least
50% reduction from baseline LDL-C levels. In high-risk
patients, the LDL-C goal is <70mg/dL (<1.8mmol/L)
and at least 50% reduction from baseline LDL-C levels.
A LDL-C goal of <1.0mmol/L (<40mg/dL) may be
considered if a patient experience a second vascular
event within 2 years (not necessarily in the same vas-
cular territory) on maximally tolerated statin therapy
(Figure 6).
 Combination therapy
To achieve such low targets, the new ESC/EAS guide-
lines emphasise the importance of combination treat-
ment, first with ezetimibe and then with a PCSK9
inhibitor. In patients with an acute coronary syndrome,
adding a PCSK9 inhibitor early after the event (if
Figure 6. Cardiovascular risk categories and treatment goals. CT: computed tomography; CKD: chronic kidney disease; DM: dia-
betes mellitus; eGFR: estimated glomerular filtration rate; FH: familial hypercholesterolaemia; SCORE: systematic coronary risk esti-
mation; TIA: transient ischaemic accident. Target organ damage is defined as microalbuminuria, retinopathy or neuropathy.
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possible, during hospitalization) should be considered.
In these patients, if the LDL-C goal is not achieved
after 4–6weeks despite maximally tolerated statin
therapy and ezetimibe, a PCSK9 inhibitor should also
be added.
 n-3 polyunsaturated fatty acids (n-3 PUFAs – fish
oils) in triglyceride management
Statin treatment remains the first choice for managing
high triglycerides (TG, >200mg/dL or 2.3mmol/L).
However when despite statin treatment high-risk
patients continue to present persistently elevated TG
(between 135–499mg/dL or 1.5 and 5.6mmol/L), n-3
PUFAs (icosapent ethyl 2 2 g daily) are recom-
mended. Fenofibrate or bezafibrate may be considered
in high-risk patients with an LDL-C at goal as a result
of statins, but in whom TG remain >200mg/dL or
>2.3mmol/L.
 Lipoprotein(a)
Lp(a) should be measured at least once in all adults.
Mendelian randomisation and epidemiologic studies
suggest very high Lp(a) indicate a lifetime atheroscler-
otic cardiovascular risk comparable to heterozygous
familial hypercholesterolaemia. Nowadays, only PCSK9
inhibitors can reduce Lp(a) by 25–30%, but new thera-
pies are awaited.
 Dyslipidaemia after 75 years
Before 75 years, statins are recommended for primary
prevention depending on the level of risk. After
75 years, initiation of statin treatment for primary
prevention may be considered (Class IIb) when at high
risk or above. In case of renal function impairment or
risk for drug interaction, the low initiation dose is pro-
gressively up titrated to achieve LDL-C goals.
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